Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1394)	3/17/2003 6:36:54 PM
From: tuck	Read Replies (1) \| Respond to of 1784

Trickle is eyeing CRL again. If it hits its numbers -- and it appears to be on track -- this is very cheap: PE of about 16, earnings growth of about 20%, yielding a PEG ratio of .75. Likely Trickle's next purchase. >>WILMINGTON, Mass.--(BUSINESS WIRE)--March 17, 2003--Charles River Laboratories' (NYSE:CRL - News) Chairman, President and Chief Executive Officer James C. Foster and Senior Vice President and Chief Financial Officer Thomas F. Ackerman will present on Tuesday, March 18, at the S.G Cowen 23rd Annual Health Care Conference in Boston. In conjunction with that presentation, and in keeping with the requirements of SEC Regulation FD, Charles River confirmed today that for the first quarter of 2003, earnings are expected to be in the range of $0.39 to $0.41 per fully-diluted share based on expected net sales growth of approximately 13% to 14%. << snip Cheers, Tuck